Download PDF
Drug Res (Stuttg) 2017; 67(03): 156-162
DOI: 10.1055/s-0042-119725
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

QSAR Differential Model for Prediction of SIRT1 Modulation using Monte Carlo Method

Ashwani Kumar
1   Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, India
,
Shilpi Chauhan
1   Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, India
› Author Affiliations
Further Information

Publication History

received 10 August 2016

accepted 20 October 2016

Publication Date:
19 December 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Silent information regulator 2 homologue one (SIRT1) modulators have therapeutic potential for a number of diseases like cardiovascular, metabolic, inflammatory and age related disorders. Here, we have studied both activators and inhibitors of SIRT1 and constructed differential quantitative structure activity relationship (QSAR) models using CORAL software by Monte Carlo optimization method and SMILES notation. 3 splits divided into 3 subsets: sub-training, calibration and test sets, were examined and validated with a prediction set. All the described models were statistically significant models. The values of sensitivity, specificity, accuracy and Matthews’ correlation coefficient for the validation set of best model were 1.0000, 0.8889, 0.9524 and 0.9058, respectively. In mechanistic interpretation, structural features important for SIRT1 activation and inhibition have been defined.

Supporting Information

 

  • References

  • 1 Ekwall K. Genome-wide analysis of HDAC function. Trends Genet 2005; 21: 608-615
    CrossrefPubMedGoogle Scholar
  • 2 Kumar A, Chauhan S. How much successful are the medicinal chemists in modulation of SIRT1: A critical review. Eur J Med Chem 2016; 119: 45-69
    CrossrefPubMedGoogle Scholar
  • 3 Benigni R. Alternatives to the carcinogenicity bioassay for toxicity prediction: are we there yet?. Expert Opin Drug Met 2012; 8: 407-417
    CrossrefPubMedGoogle Scholar
  • 4 Mor S, Nagoria S, Kumar A et al. QSAR studies and design of some tetracyclic 1,4-benzothiazines as antimicrobial agents. Drug Res (Stuttg) 2016; 66: 436-443
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Bansal A, Kumar P, Narasimhan B. Synthesis, antimicrobial evaluation and QSAR studies of 2-hydroxy propanoic acid derivatives. Drug Res (Stuttg) 2014; 64: 240-245
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Fernández A, Lombardo A, Rallo R et al. Quantitative consensus of bioaccumulation models for integrated testing strategies. Expert Opin Drug Metab Toxicol 2012; 45: 51-58
    PubMedGoogle Scholar
  • 7 CORAL . http://www.insilico.eu/coral/ Accessed on May 9, 2016
    PubMed
  • 8 Toropov AA, Toropova AP. CORAL software: prediction of carcinogenicity of drugs by means of the Monte Carlo method. Eur J Pharm Sci 2014; 52: 21-25
    CrossrefPubMedGoogle Scholar
  • 9 Worachartcheewan A, Nantasenamat C, Isarankura-Na-Ayudhya C et al. QSAR study of H1N1 neuraminidase inhibitors from influenza A virus. Lett Drug Des Discov 2014; 11: 420-427
    CrossrefPubMedGoogle Scholar
  • 10 Martinez JCG, Duchowicz PR, Estrada MR et al. QSAR study and molecular design of open-chain enaminones as anticonvulsant agents. Int J Mol Sci 2011; 12: 9354-9368
    CrossrefPubMedGoogle Scholar
  • 11 Masand VH, Toropov AA, Toropova AP et al. QSAR models for antimalarial activity of 4-aminoquinolines. Curr Comput Aided Drug Des 2014; 10: 75-82
    CrossrefPubMedGoogle Scholar
  • 12 Toropova AP, Toropov AA, Veselinovic JB et al. QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method. Eur J Med Chem 2014; 77: 298-305
    CrossrefPubMedGoogle Scholar
  • 13 Toropov AA, Toropova AP, Benfenati E et al. QSAR models for inhibitors of physiological impact of Escherichia coli that leads to diarrhea. Biochem Biophys Res Commun 2013; 432: 214-225
    CrossrefPubMedGoogle Scholar
  • 14 Mullen LMA, Duchowicz PR, Castro EA. QSAR treatment on a new class of triphenylmethyl-containing compounds as potent anticancer agents. Chemometr Intell Lab Syst 2011; 107: 269-275
    CrossrefPubMedGoogle Scholar
  • 15 Worachartcheewan A, Mandi P, Prachayasittikul V et al. Large-scale QSAR study of aromatase inhibitors using SMILES-based descriptors. Chemometr Intell Lab Syst 2014; 138: 120-126
    CrossrefPubMedGoogle Scholar
  • 16 García J, Duchowicz PR, Rozas MF et al. A comparative QSAR on 1,2,5-thiadiazolidin-3-one 1,1-dioxide compounds as selective inhibitors of human serine proteinases. J Mol Graph Model 2011; 31: 10-19
    CrossrefPubMedGoogle Scholar
  • 17 Bemis JE, Vu CB, Xie R et al. Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg Med Chem Lett 2009; 19: 2350-2353
    CrossrefPubMedGoogle Scholar
  • 18 Vu CB, Bemis JE, Disch JS et al. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. J Med Chem 2009; 52: 1275-1283
    CrossrefPubMedGoogle Scholar
  • 19 Cohen HY, Miller C, Bitterman KJ et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-392
    CrossrefPubMedGoogle Scholar
  • 20 Bemis JE, Disch JS, Ng PY et al. Sirtuin modulating compounds. US Patent 2011; 7,893,086
    PubMedGoogle Scholar
  • 21 Oalmann C, Perni RB, Disch JS et al. Patent Appl; PCT WO 2009/00058348
    PubMed
  • 22 Yang H, Zhang W, Pan H et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kB activity. PLoS ONE 2012; 7: 1-11
    PubMedGoogle Scholar
  • 23 Grozinger CM, Chao ED, Blackwell HE et al. Identification of a class of small molecule inhibitors of the sirtuins family of NAD+-dependent deacetylase by phenotypic screening. J Biol Chem 2001; 276: 38837-38843
    CrossrefPubMedGoogle Scholar
  • 24 Heltweg B, Gatbonton T, Schuler AD et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-4377
    CrossrefPubMedGoogle Scholar
  • 25 Huber K, Schemies J, Uciechowska U et al. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+-dependent histone deacetylases (sirtuins). J Med Chem 2010; 53: 1383-1386
    CrossrefPubMedGoogle Scholar
  • 26 Lain S, Hollick JJ, Campbell J et al. Discovery, in vivo activity, and mechanism of action of a small molecule p53 activator. Cancer Cell 2008; 13: 454-463
    CrossrefPubMedGoogle Scholar
  • 27 Lara E, Mai A, Calvanese V et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2008; 28: 781-791
    PubMedGoogle Scholar
  • 28 Medda F, Russell RJM, Higgins M et al. Novel Cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem 2009; 52: 673-682
    PubMedGoogle Scholar
  • 29 Napper AD, Hixon J, McDonagh T et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005; 48: 8045-8054
    CrossrefPubMedGoogle Scholar
  • 30 Nayagam VM, Wang X, Tan YC et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006; 11: 1-8
    CrossrefPubMedGoogle Scholar
  • 31 Sanders BD, Jackson B, Brent M et al. Identification and characterization of novel sirtuin inhibitor scaffolds. Bioorg Med Chem 2009; 17: 7031-7041
    CrossrefPubMedGoogle Scholar
  • 32 Suzuki T, Imai K, Imai E et al. Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Bioorg Med Chem 2009; 17: 5900-5905
    CrossrefPubMedGoogle Scholar
  • 33 Suzuki T, Imai K, Nakagawa H et al. 2-Anilinobenzamides as SIRT inhibitors. Chem Med Chem 2006; 1: 1059-1062
    CrossrefPubMedGoogle Scholar
  • 34 Tavares J, Ouaissi A, Lin PKT et al. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. Chem Med Chem 2010; 5: 140-147
    CrossrefPubMedGoogle Scholar
  • 35 Trapp J, Meier R, Hongwiset D et al. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). Chem Med Chem 2007; 2: 1419-1431
    CrossrefPubMedGoogle Scholar
  • 36 Uciechowska U, Schemies J, Neugebauer RC et al. Thiobarbiturates as sirtuin inhibitors: virtual screening, free energy calculations, and biological testing. Chem Med Chem 2008; 3: 1965-1976
    CrossrefPubMedGoogle Scholar
  • 37 Choi G, Lee J, Ji JY et al. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects. Int J Oncol 2013; 43: 1205-1211
    CrossrefPubMedGoogle Scholar
  • 38 Asaba T, Suzuki T, Ueda R et al. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. J Am Chem Soc 2009; 131: 6989-6996
    CrossrefPubMedGoogle Scholar
  • 39 Toropov AA, Toropova AP, Benfenati E et al. The definition of the molecular structure for potential anti-malaria agents by the Monte Carlo method. Struct Chem 2013; 24: 1369-1381
    CrossrefPubMedGoogle Scholar
  • 40 OpenBabel version 2.3.2
    PubMed
  • 41 Toropova AP, Toropov AA, Benfenati E et al. CORAL: quantitative structure–activity relationship models for estimating toxicity of organic compounds in rats. J Comput Chem 2011; 32: 2727-2733
    CrossrefPubMedGoogle Scholar
  • 42 Benfenati E, Toropov AA, Toropova AP et al. CORAL Software: QSAR for Anticancer Agents. Chem Biol Drug Des 2011; 77: 471-476
    CrossrefPubMedGoogle Scholar
  • 43 Cooper JA, Saracci R, Cole P. Describing the validity of carcinogen screening tests. Br J Cancer 1979; 39: 87-89
    CrossrefPubMedGoogle Scholar
  • 44 Toropov AA, Toropova AP, Rasulev BF et al. CORAL: Binary Classifications (Active/Inactive) for Liver-Related Adverse Effects of Drugs. Curr Drug Saf 2012; 7: 257-261
    CrossrefPubMedGoogle Scholar
  • 45 Toropov AA, Toropova AP, Benfenati E et al. CORAL: classification model for predictions of anti-sarcoma activity. Curr Top Med Chem 2012; 12: 2741-2744
    PubMedGoogle Scholar
  • 46 Toropov AA, Toropova AP, Lombardo A et al. CORAL: the prediction of biodegradation of organic compounds with optimal SMILES-based descriptors. Cent Eur J Chem 2012; 10: 1042-1048
    PubMedGoogle Scholar
  • 47 Manganelli S, Benfenati E, Manganaro A et al. New Quantitative Structure–Activity Relationship Models Improve Predictability of Ames Mutagenicity for Aromatic Azo Compounds. Tox Sci 2016; 1-11
    PubMedGoogle Scholar
  • 48 Aher RB, Roy K. First report on exploring classification and regression based QSAR modelling of Plasmodium falciparum glycogen synthase kinase (PfGSK-3) inhibitors. SAR QSAR Environ Res 2015; 26: 959-976
    PubMedGoogle Scholar
  • 49 Ojha PK, Roy K. Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection. Chemometr Intell Lab 2011; 109: 146-161
    CrossrefPubMedGoogle Scholar
  • 50 Toropov AA, Toropova AP, Lombardo A et al. CORAL: Building up the model for bioconcentration factor and defining it’s applicability domain. Eur J Med Chem 2011; 46: 1400-1403
    CrossrefPubMedGoogle Scholar
  • 51 Kumar A, Chauhan S. Use of Monte Carlo method for OECD principles guided QSAR modelling of SIRT1 inhibitors. Arch Pharm 2016 (under communication)
    PubMed
  • 52 Cao D, Wang M, Qiu X et al. Structural basis for allosteric substrate dependent stimulation of SIRT1 activity by resveratrol. Genes Dev 2015; 29: 1316-1325
    CrossrefPubMedGoogle Scholar
  • 53 Wu J, Zhang D, Chen L et al. Discovery and mechanism study of SIRT1 activators that promote the deacetylation of fluorophore-labeled substrate. J Med Chem 2013; 56: 761-780
    CrossrefPubMedGoogle Scholar
  • 54 Mahajan SS, Scian M, Sripathy S et al. Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem 2014; 57: 3283-3294
    CrossrefPubMedGoogle Scholar